<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The combination of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and donor lymphocyte infusions (DLI) as first salvage therapy for relapse after allogeneic transplantation (allo-HSCT) was studied in 30 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n=28) or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n=2) within a prospective single-arm multicenter phase-II trial </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment schedule contained up to eight cycles <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (100 mg/m(2)/day, days 1-5, every 28 days) followed by DLI (from 1-5 × 10(6) to 1-5 × 10(8) CD3(+)cells/kg) after every second <z:chebi fb="0" ids="2038">azacitidine</z:chebi> cycle </plain></SENT>
<SENT sid="2" pm="."><plain>A median of three courses <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (range 1-8) were administered, and 22 patients (73%) received DLI </plain></SENT>
<SENT sid="3" pm="."><plain>Overall response rate was 30%, including seven complete remissions (CRs, 23%) and two partial remissions (7%) </plain></SENT>
<SENT sid="4" pm="."><plain>Five patients remain in CR for a median of 777 days (range 461-888) </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes were more likely to respond (P=0.011), and a lower blast count (P=0.039) as well as high-risk cytogenetics (P=0.035) correlated with the likelihood to achieve CR </plain></SENT>
<SENT sid="6" pm="."><plain>Incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> was 37% and 17%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001875'>Neutropenia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> grade III/IV occurred during 65% and 63% of treatment cycles, while <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were the most common grade III/IV non-hematological toxicity </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> and DLI as salvage therapy is safe, induces long-term remissions and may become an alternative for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> relapsing after allo-HSCT </plain></SENT>
</text></document>